Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 73
Filter
1.
Mikrochim Acta ; 187(7): 402, 2020 06 23.
Article in English | MEDLINE | ID: mdl-32572633

ABSTRACT

New multi-walled carbon nanotubes supported on Ti3C2-MXene and chitosan (chit) composite film-based electrochemical sensor for ifosfamide (IFO), acetaminophen (ACOP), domperidone (DOM), and sumatriptan (SUM) have been developed. Ti3C2-MXene was synthesized by a fluoride method. Structural and chemical characterizations suggested the successful preparation of Ti3C2-MXene with clearly seen layered morphology, defined 0 0 2 diffraction peak at 7.5° and complete absence of 1 0 4 plane at 39°. The electrochemical performance of the sensor was investigated by cyclic voltammetry and adsorptive stripping differential pulse voltammetry. The Ti3C2/MWCNT/Chit modified glassy carbon electrode exhibits enhanced electrocatalytic activities toward the oxidation of target analytes. Excellent conductivity, large surface area, and high catalytic properties of the Ti3C2-MXene showed synergistic effects with MWCNTs and helped in achieving low detection limits of targets with high selectivity and reproducibility. The assay allows determination of IFO, ACOP, DOM, and SUM in the concentration ranges 0.0011-1.0, 0.0042-7.1, 0.0046-7.3, and 0.0033-61 µM with low detection limits of 0.00031, 0.00028, 0.00034, and 0.00042 µM, respectively. The sensor was successfully applied for voltammetric screening of target analytes in urine and blood serum samples with recoveries > 95.21%. Schematic illustration of the synthesis of self-assembled MXene/MWCNT/chitosan nanocomposite is given and its application to the voltammetric determination of ifosfamide, acetaminophen, domperidone, and sumatriptan described. Graphical abstract.


Subject(s)
Chitosan/chemistry , Electrochemical Techniques/methods , Nanocomposites/chemistry , Nanotubes, Carbon/chemistry , Titanium/chemistry , Acetaminophen/blood , Acetaminophen/urine , Domperidone/blood , Domperidone/urine , Humans , Ifosfamide/blood , Ifosfamide/urine , Limit of Detection , Reproducibility of Results , Sumatriptan/blood , Sumatriptan/urine
2.
Int J Pharm Pract ; 28(5): 506-511, 2020 Oct.
Article in English | MEDLINE | ID: mdl-31663186

ABSTRACT

OBJECTIVE: The objective of this study was to evaluate the frequency of genetic lesions in pharmacists and nurses who prepare and/or handle antineoplastic agents and to evaluate whether there are traces of contaminants in the urine of these professionals. METHODS: A total of 59 professionals participated in the study, of which 10 were non-exposed professionals (controls), 25 were pharmacists, and 24 were nurses. KEY FINDINGS: There was a significant increase in genetic damage in lymphocytes and cells of the oral mucosa in both pharmacists and nurses. The levels of cyclophosphamide and ifosfamide were also increased in the urine samples from those individuals. CONCLUSIONS: These results demonstrate the growing need for genetic biomonitoring and biomonitoring of trace antineoplastic agents in the urine of health professionals who prepare and/or handle antineoplastic agents.


Subject(s)
Antineoplastic Agents/urine , Biological Monitoring/statistics & numerical data , Nurses/statistics & numerical data , Occupational Exposure/adverse effects , Pharmacists/statistics & numerical data , Adult , Antineoplastic Agents/adverse effects , Antineoplastic Agents/blood , Biological Monitoring/methods , Case-Control Studies , Cyclophosphamide/adverse effects , Cyclophosphamide/blood , Cyclophosphamide/urine , DNA Damage/drug effects , Drug Compounding , Female , Humans , Ifosfamide/adverse effects , Ifosfamide/blood , Ifosfamide/urine , Lymphocytes/drug effects , Male , Middle Aged , Mouth Mucosa/drug effects , Occupational Exposure/statistics & numerical data , Young Adult
3.
Sci Rep ; 9(1): 16621, 2019 11 12.
Article in English | MEDLINE | ID: mdl-31719649

ABSTRACT

Grapefruit juice (GFJ) and naringin when consumed previously or together with medications may alter their bioavailavility and consequently the clinical effect. Ifosfamide (IF) is an antitumoral agent prescribed against various types of cancer. Nevertheless, there is no information regarding its interaction with the ingestion of GFJ or naringin. The aims of the present report were validating a method for the quantitation of IF in the plasma of mouse, and determine if mice pretreated with GFJ or naringin may modify the IF pharmacokinetics. Our HPLC results to quantify IF showed adequate intra and inter-day precision (RSD < 15%) and accuracy (RE < 15%) indicating reliability. Also, the administration of GFJ or naringin increased Cmax of IF 22.9% and 17.8%, respectively, and decreased Tmax of IF 19.2 and 53.8%, respectively. The concentration of IF was higher when GFJ (71.35 ± 3.5 µg/mL) was administered with respect to that obtained in the combination naringin with IF (64.12 ± µg/mL); however, the time required to reach such concentration was significantly lower when naringin was administered (p < 0.5). We concluded that pre-administering GFJ and naringin to mice increased the Tmax and decreased the Cmax of IF.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Citrus paradisi/adverse effects , Flavanones/adverse effects , Food-Drug Interactions , Fruit and Vegetable Juices/adverse effects , Ifosfamide/pharmacokinetics , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/blood , Chromatography, High Pressure Liquid , Drug Interactions , Ifosfamide/administration & dosage , Ifosfamide/blood , Male , Mice , Mice, Inbred ICR
4.
Biosens Bioelectron ; 120: 22-29, 2018 Nov 30.
Article in English | MEDLINE | ID: mdl-30144642

ABSTRACT

The simultaneous measurement of the concentration of anticancer drugs with a fast, sensitive and accurate method in biological samples is a challenge for better monitoring of drug therapy and better determine the pharmacokinetics. An electrochemical sensor was developed for the simultaneous determination of anticancer drugs, Ifosfamide (IFO) and Etoposide (ETO) based on pencil graphite electrode modified with Au/Pd@rGO nanocomposite decorated with poly (L-Cysteine). Cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) were utilized to study the properties of the modified electrode. The electrochemical behavior of IFO and ETO on the Au/Pd@rGO@p(L-Cys) modified electrode was investigated by cyclic voltammetry and differential pulse voltammetry (DPV) techniques and the obtained results confirmed its efficiency for the individual and simultaneous sensing of IFO and ETO. After optimization of electrochemical parameters, the fabricated sensor presented excellent performance in simultaneous determination of IFO and ETO with a wide linear range from 0.10 to 90.0 µM and 0.01 to 40.0 µM and low detection limits (3 Sb/m) of 9.210 nM and 0.718 nM, respectively. In addition, this study proved that the constructed sensor could be useful to simultaneous analysis of IFO and ETO in biological samples and pharmaceutical compounds.


Subject(s)
Biosensing Techniques/methods , Cysteine/chemistry , Electrochemical Techniques , Etoposide/analysis , Ifosfamide/analysis , Nanocomposites/chemistry , Antineoplastic Agents/analysis , Electrodes , Etoposide/blood , Graphite/chemistry , Ifosfamide/blood , Limit of Detection
5.
PLoS One ; 10(11): e0143421, 2015.
Article in English | MEDLINE | ID: mdl-26600181

ABSTRACT

Ifosfamide blood concentrations are necessary to monitor its therapeutic response, avoiding any adverse effect. We developed and validated an analytical method by UPLC-MS/MS to quantify ifosfamide in dried blood spots (DBS). Blood samples were collected on Whatman 903® filter paper cards. Five 3 mm disks were punched out from each dried blood spot. Acetonitrile and ethyl acetate were used for drug extraction. Chromatographic separation was carried out in an Acquity UPLC equipment with a BEH-C18 column, 2.1 x 100 mm, 1.7 µm (Waters®). The mobile phase consisted in 5 mM ammonium formate and methanol:acetonitrile (40:48:12 v/v/v) at 0.2 mL/min. LC-MS/MS detection was done by ESI+ and multiple reaction mode monitoring, ionic transitions were m/z1+ 260.99 > 91.63 for ifosfamide and 261.00 > 139.90 for cyclophosphamide (internal standard). This method was linear within a 100-10000 ng/mL range and it was accurate, precise and selective. Ifosfamide samples in DBS were stable for up to 52 days at -80°C. The procedure was tested in 14 patients, ages 1 month to 17 years (9 males and 5 females), with embryonic tumours treated with ifosfamide, alone or combined, at a public tertiary referral hospital. Ifosfamide blood levels ranged from 11.1 to 39.7 µmol/L at 12 hours after the last infusion, while 24-hour levels ranged from 0.7-19.7 µmol/L. The median at 12 hours was 19.5 µmol/L (Q25 14.4-Q75 29.0) and 3.8 µmol/L (Q25 1.5-Q75 9.9) at 24 hours, p<0.001. This method is feasible to determine ifosfamide plasma levels in paediatric patients.


Subject(s)
Chromatography, High Pressure Liquid/methods , Dried Blood Spot Testing/methods , Ifosfamide/blood , Neoplasms, Germ Cell and Embryonal/blood , Tandem Mass Spectrometry/methods , Adolescent , Child , Child, Preschool , Cyclophosphamide , Demography , Female , Hematocrit , Humans , Infant , Infant, Newborn , Male , Reproducibility of Results
6.
Article in English | MEDLINE | ID: mdl-25939095

ABSTRACT

The antitumor drug, ifosfamide (IFO), requires activation by cytochrome P450 (CYP) to form the active metabolite, 4-hydroxyisfosfamide (4-OHIFO), leading to toxic by-products at high dose. In order to overcome these drawbacks, preactivated ifosfamide derivatives (RXIFO) were designed to release 4-OHIFO without CYP involvement. A high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed for the simultaneous quantification of 4-OHIFO, IFO and four derivatives RXIFO in mouse plasma using multiple reaction monitoring. Because of its instability in plasma, 4-OHIFO was immediately converted to the semi-carbazone derivative, 4-OHIFO-SCZ. For the six analytes, the calibration curves were linear from 20 to 5000ng/mL in 50µL plasma and the lower limit of quantitation was determined at 20ng/mL with accuracies within ±10% of nominal and precisions less than 12%. Their recoveries ranged from 62 to 96% by using liquid-liquid extraction. With an improved assay sensitivity compared to analogues, the derivative 4-OHIFO-SCZ was stable in plasma at 4°C for 24h and at -20°C for three months. For all compounds, the assay was validated with accuracies within ±13% and precisions less than 15%. This method was applied to a comparative pharmacokinetic study of 4-OHIFO from IFO and three derivatives RXIFO in mice. This active metabolite was produced by some of the novel conjugates with good pharmacokinetic properties.


Subject(s)
Chromatography, High Pressure Liquid/methods , Ifosfamide/analogs & derivatives , Ifosfamide/blood , Tandem Mass Spectrometry/methods , Animals , Drug Stability , Female , Ifosfamide/chemistry , Ifosfamide/pharmacokinetics , Linear Models , Mice , Reproducibility of Results , Sensitivity and Specificity
7.
Alcohol ; 48(7): 707-15, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25262573

ABSTRACT

This study investigated the effects of umbelliferone (UF) on alcoholic fatty liver and its underlying mechanism. Rats were fed a Lieber-DeCarli liquid diet with 36% of calories as alcohol with or without UF (0.05 g/L) for 8 weeks. Pair-fed rats received an isocaloric carbohydrate liquid diet. UF significantly reduced the severity of alcohol-induced body weight loss, hepatic lipid accumulation and droplet formation, and dyslipidemia. UF decreased plasma AST, ALT, and γGTP activity. UF significantly reduced hepatic cytochrome P450 2E1 activities and increased alcohol dehydrogenase and aldehyde dehydrogenase 2 activities compared to the alcohol control group, which resulted in a lower plasma acetaldehyde level in the rats that received UF. Chronic alcohol exposure inhibited hepatic AMPK activation compared to the pair-fed rats, which was reversed by UF supplementation. UF also significantly suppressed the lipogenic gene expression (SREBP-1c, SREBP-2, FAS, CIDEA, and PPARγ) and elevated the fatty acid oxidation gene expression (PPARα, Acsl1, CPT, Acox, and Acaa1a) compared to the alcohol control group, which could lead to inhibition of FAS activity and stimulation of CPT and fatty acid ß-oxidation activities in the liver of chronic alcohol-fed rats. These results indicated that UF attenuated alcoholic steatosis through down-regulation of SREBP-1c-mediated lipogenesis and up-regulation of PPARα-mediated fatty acid oxidation. Therefore, UF may provide a promising natural therapeutic strategy against alcoholic fatty liver.


Subject(s)
Fatty Liver, Alcoholic/drug therapy , PPAR alpha/drug effects , Sterol Regulatory Element Binding Protein 1/drug effects , Umbelliferones/therapeutic use , Alcohol Dehydrogenase/metabolism , Aldehyde Dehydrogenase/metabolism , Aldehyde Dehydrogenase, Mitochondrial , Animals , Cytochrome P-450 CYP2E1/metabolism , Dietary Supplements , Hypolipidemic Agents/therapeutic use , Ifosfamide/analogs & derivatives , Ifosfamide/blood , Liver/drug effects , Liver/enzymology , Male , Mitochondrial Proteins/metabolism , PPAR alpha/physiology , Rats , Rats, Sprague-Dawley , Sterol Regulatory Element Binding Protein 1/physiology
8.
J Clin Pharmacol ; 52(1): 55-64, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21263015

ABSTRACT

Ifosfamide (IFO), which is used in the treatment of pediatric solid tumors, causes high rates of nephrotoxicity. N-acetylcysteine (NAC), an antidote for acetaminophen overdose, has been shown to prevent IFO-induced renal cell death and nephrotoxicity in both LLCPK-1 cells and a rat model. To facilitate the use of NAC in preventing IFO-induced nephrotoxicity in children, the authors compared the systemic exposure to NAC in children treated for acetaminophen overdose to the systemic exposure of the therapeutically effective rat model. The mean systemic exposure in the rat model was 18.72 mM·h (range, 9.92-30.02 mM·h), compared to the mean systemic exposure found in treated children (14.48 mM·h; range, 6.22-32.96 mM·h). They also report 2 pediatric cases in which NAC-attenuated acute renal failure associated with IFO when given concurrently with their chemotherapy treatment. Systemic exposure to NAC measured in 1 of these cases was comparable to that in the children treated for acetaminophen overdose. These results corroborate NAC's potential to protect against IFO-induced nephrotoxicity in children when used in its clinically approved dose schedule and supports a clinical trial in children.


Subject(s)
Acetylcysteine/pharmacokinetics , Acetylcysteine/therapeutic use , Acute Kidney Injury/prevention & control , Protective Agents/pharmacokinetics , Protective Agents/therapeutic use , Acetaminophen/toxicity , Acetylcysteine/blood , Acute Kidney Injury/chemically induced , Acute Kidney Injury/metabolism , Adolescent , Analgesics, Non-Narcotic/toxicity , Animals , Antineoplastic Agents, Alkylating/adverse effects , Antineoplastic Agents, Alkylating/blood , Antineoplastic Agents, Alkylating/pharmacokinetics , Area Under Curve , Child , Drug Overdose/drug therapy , Female , Humans , Ifosfamide/adverse effects , Ifosfamide/blood , Ifosfamide/pharmacokinetics , Male , Rats , Rats, Wistar
9.
J Chromatogr B Analyt Technol Biomed Life Sci ; 879(11-12): 743-50, 2011 Apr 01.
Article in English | MEDLINE | ID: mdl-21377940

ABSTRACT

Among antitumor oxazaphosphorine drugs, the prodrug ifosfamide (IFO) and its analogs require metabolic activation by specific liver cytochrome P450 (CYP) enzymes to become therapeutically active. New 7,9-dimethyl-ifosfamide analogs have shown greater cytotoxic activity than IFO, whereas side-chain oxidation still occurred leading to monochloroacetone after N-dechloropropylation. A sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed and validated for the simultaneous quantitation of the prodrug 7S,9S-dimethyl-ifosfamide (diMeIFO) and its two inactive metabolites, N(2)- and N(3)-deschloropropyl-dimethylifosfamide (N(2)-DCP-diMeIFO and N(3)-DCP-diMeIFO) in mouse plasma. After protein precipitation with methanol, the analytes were separated by isocratic reversed-phase chromatography with (methanol/ammonium formate pH 5.5, 60:40, v/v) and detected by tandem mass spectrometry using multiple reaction monitoring of transitions ions m/z 289→168 for diMeIFO, m/z 213→168 for N(2)-DCP-diMeIFO, m/z 213→92 for N(3)-DCP-diMeIFO and m/z 261→154 for IFO (internal standard). The calibration curves were linear over the concentration range of 20-10,000ng/mL for the three analytes. Mean extraction recoveries from mouse plasma were 99, 96, 99 and 100% for diMeIFO, N(2)-DCP-diMeIFO, N(3)-DCP-diMeIFO and IFO, respectively. The lower limit of quantitation for diMeIFO and its metabolites was 20 ng/mL in 50 µL plasma. The method was accurate with calculated bias from -5.8 to 4.0% for diMeIFO, from -1.1 to 10.6% for N(2)-DCP-diMeIFO and from -6.9 to 9.8% for N(3)-DCP-diMeIFO, and precise with coefficients of variation lower than 6.8%, 7.8% and 14.3%, respectively. The assay was successfully applied to a preliminary pharmacokinetic study of diMeIFO and of its metabolites in mice.


Subject(s)
Chromatography, Liquid/methods , Ifosfamide/analogs & derivatives , Ifosfamide/blood , Tandem Mass Spectrometry/methods , Animals , Drug Stability , Female , Humans , Ifosfamide/pharmacokinetics , Least-Squares Analysis , Mice , Mice, Nude , Reproducibility of Results , Rhabdomyosarcoma/blood , Rhabdomyosarcoma/metabolism , Sensitivity and Specificity
10.
J Pharm Biomed Anal ; 45(2): 295-303, 2007 Oct 18.
Article in English | MEDLINE | ID: mdl-17855037

ABSTRACT

A sensitive and specific liquid chromatography-mass spectrometry (LC-MS) method has been developed and validated for the enantioselective determination of ifosfamide [(R)-IF and (S)-IF] in human plasma and for the detection of the N-dechloroethylated metabolites of IF, 2-N-dechloroethylifosfamide [(R)-2-DCl-IF and (S)-2-DCl-IF] and 3-N-dechloroethylifosfamide [(R)-3-DCl-IF and (S)-3-DCl-IF]. IF, 2-DCl-IF and 3-DCl-IF were extracted from plasma using solid-phase extraction and resolved by liquid chromatography on a column containing a Chirabiotic T chiral stationary phase. The enantioselective separations were achieved using a mobile phase composed of 2-propanol:methanol (60:40, v/v) and a flow rate of 0.5 ml/min. The observed enantioselectivities (alpha) for IF, 2-DCl-IF and 3-DCl-IF were 1.20, 1.17 and 1.20, respectively. The calibration curve was linear in the concentration range of 37.50-4800 ng/ml for each ifosfamide enantiomer (r(2)>0.997). The lower limit of detection (LLOD) was 5.00 ng/ml. The inter- and intra-day precision ranged from 3.63 to 15.8% relative standard deviation (R.S.D.) and 10.1 to 14.3% R.S.D., respectively, and the accuracy ranged from 89.2 to 101.5% of the nominal values. The method was applied to the analysis of plasma samples obtained from a cancer patient who received 3.75 g/m(2)/day dose of (R,S)-ifosfamide as a 96-h continuous infusion.


Subject(s)
Chromatography, Liquid/methods , Ifosfamide/analogs & derivatives , Mass Spectrometry/methods , Chromatography, Liquid/instrumentation , Humans , Ifosfamide/blood , Ifosfamide/chemistry , Molecular Structure , Reference Standards , Reproducibility of Results , Sensitivity and Specificity , Solid Phase Extraction , Stereoisomerism
11.
Drug Metab Dispos ; 35(10): 1721-4, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17600085

ABSTRACT

Dexamethasone induces the hepatic cytochrome P450 3A and, therefore, is predicted to change the pharmacokinetics, activities, and side effects of drugs metabolized by cytochrome P450 3A. The aim of this study was to determine whether the pharmacokinetics of the cytochrome P450 3A-dependent oxazaphosphorine cytostatic drug ifosfamide is influenced by short-term antiemetic use of dexamethasone in patients. The peak concentration and area under the curve (AUC) were determined for the parent compound and the metabolites 4-hydroxyifosfamide and chloracetaldehyde in eight patients who received two cycles of ICE chemotherapy (ifosfamide 5 g/m(2) day 1, carboplatin 300 mg/m(2) day 1, etoposide 100 mg/m(2) days 1-3). One cycle included concomitant administration of dexamethasone (40 mg over 30 min, 16 h and 1 h before chemotherapy), whereas the other did not. The half-lives of ifosfamide, 4-hydroxyifosfamide, and chloracetaldehyde were shorter with concomitant administration of dexamethasone, but the differences were not statistically significant. In addition, there were no significant differences in the ifosfamide and active 4-hydroxyifosfamide peak concentrations and AUCs when dexamethasone was included. After dexamethasone administration, the chloracetaldehyde peak concentration was slightly increased by 1.5-fold and the AUC by 1.3-fold; however, these increases were not statistically significant. In conclusion, dexamethasone comedication in ICE chemotherapy did not change the ifosfamide pharmacokinetics. Thus, dexamethasone can be used safely as an antiemetic drug in ifosfamide chemotherapy.


Subject(s)
Antiemetics/therapeutic use , Antineoplastic Agents, Alkylating/pharmacokinetics , Dexamethasone/therapeutic use , Ifosfamide/pharmacokinetics , Neoplasms/drug therapy , Acetaldehyde/analogs & derivatives , Acetaldehyde/blood , Adolescent , Adult , Aged , Antineoplastic Agents, Alkylating/blood , Antineoplastic Agents, Alkylating/therapeutic use , Female , Humans , Ifosfamide/blood , Ifosfamide/therapeutic use , Male , Middle Aged , Neoplasms/metabolism
12.
J Pharm Biomed Anal ; 37(5): 1025-9, 2005 Apr 29.
Article in English | MEDLINE | ID: mdl-15862682

ABSTRACT

In man, neurotoxicity associated to ifosfamide treatment can be reversed by intravenous thiamine administration. Trying to explain this clinical finding, we decided to study possible changes in thiamine availability and activation in patients exposed to ifosfamide. Free thiamine and its phosphate esters levels were measured in plasma, erythrocytes and urine by an ion-pair HPLC method with pre-column derivatization, which allowed separation of the fluorescent compounds in less than 10 min. The method was validated by linearity, sensitivity and reproducibility studies, whose values met the demands for bioanalytical assays. This method was applied to assess thiamine status in cancer patients exposed to ifosfamide therapy for advanced disease.


Subject(s)
Erythrocytes/metabolism , Neoplasms/blood , Neoplasms/urine , Thiamine/blood , Thiamine/urine , Chromatography, High Pressure Liquid/methods , Humans , Ifosfamide/blood , Ifosfamide/therapeutic use , Ifosfamide/urine , Neoplasms/drug therapy , Phosphorylation , Spectrometry, Fluorescence/methods
13.
J Pediatr Hematol Oncol ; 26(11): 764-7, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15543015

ABSTRACT

The combination of irinotecan (daily for 5 days for 2 consecutive weeks) and ifosfamide (daily on days 1 through 3) was investigated in children with osteosarcoma. Irinotecan pharmacokinetic investigations were performed before ifosfamide (day 1), after 3 days of ifosfamide (day 3), and 9 days after the end of ifosfamide (day 12). On day 3, the concentrations of irinotecan's active metabolite, SN-38, were below the limit of quantitation in two patients and were decreased in a third patient. The SN-38 area under the concentration-time curve remained below the day 1 value in two patients on day 12. The reduced area under the curve to the active metabolite SN-38 during ifosfamide therapy predicts a compromised efficacy of irinotecan in this combination.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Camptothecin/analogs & derivatives , Camptothecin/pharmacokinetics , Ifosfamide/pharmacology , Osteosarcoma/drug therapy , Adolescent , Adult , Area Under Curve , Camptothecin/administration & dosage , Camptothecin/blood , Camptothecin/metabolism , Drug Interactions , Female , Humans , Ifosfamide/administration & dosage , Ifosfamide/blood , Irinotecan , Male , Pharmacokinetics
14.
Cancer Chemother Pharmacol ; 53(6): 496-502, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15138712

ABSTRACT

Trofosfamide (TRO), like cyclophosphamide (CYCLO) and ifosfamide (IFO), is a prodrug oxazaphosphorine derivative that requires hepatic biotransformation to form the cytotoxically active 4-hydroxy derivative (4-hydroxy-TRO). Individual 4-hydroxyoxazaphosphorines and 4-hydroxy-TRO itself have not been demonstrated in humans up to now. For investigation of the principal pharmacokinetics of TRO and its metabolites, six tumour patients (49-65 years of age, Karnofsky index >70%) with normal liver and renal function were given a single oral dose of 600 mg/m(2) TRO. Plasma was sampled using a bedside technique. Individual 4-hydroxyoxazaphosphorines and TRO together with further metabolites were determined by a specially developed HPLC-UV method and a HPLC-MS method, respectively. With a short apparent half-life (1.2 h) and high apparent clearance (Cl/F 4.0 l/min), TRO was very quickly eliminated from plasma and highly converted to its metabolites, mainly 4-hydroxy-TRO and IFO. In relation to the AUC values of TRO (1.0) the following molar quotients were calculated: 1.59 (4-hydroxy-TRO), 0.40 (4-hydroxy-IFO), 6.90 (IFO) and 0.74 (CYCLO). C(max) values were in the range 10-13 micromol/l for TRO, 4-hydroxy-TRO and IFO and in the range 1.5-4.0 micromol/l for CYCLO, 2- and 3-dechloroethyl-IFO and 4-hydroxy-IFO. Kinetic data indicate that 4-hydroxy-IFO is formed by both hydroxylation of TRO and exocyclic N-dechloroethylation of 4-hydroxy-TRO. 4-hydroxy-CYCLO was not detected above the quantification limit of the method. Only mild haemodepressive side effects were observed after oral administration of 600 mg/m(2) TRO. In relation to known data for IFO, TRO is much more 4-hydroxylated than IFO. The high 4-hydroxy-TRO/TRO ratio found suggests that TRO is a promising tumourstatic agent.


Subject(s)
Antineoplastic Agents, Alkylating/pharmacokinetics , Cyclophosphamide/analogs & derivatives , Cyclophosphamide/pharmacokinetics , Lymphoproliferative Disorders/metabolism , Administration, Oral , Aged , Antineoplastic Agents, Alkylating/administration & dosage , Area Under Curve , Cyclophosphamide/administration & dosage , Female , Humans , Ifosfamide/blood , Lymphoproliferative Disorders/pathology , Male , Middle Aged
15.
Int J Clin Pharmacol Res ; 23(1): 1-7, 2003.
Article in English | MEDLINE | ID: mdl-14621067

ABSTRACT

This phase I study was designed to evaluate the activity toxicity and pharmacokinetics of docetaxel combined with ifosfamide in the treatment of hormone-refractory prostate cancer. Ten patients received a median of 4.6 treatment cycles. Docetaxel was administered at a dose of 40 mg/m2 in a 1-hour infusion followed by ifosfamide 3,000 mg/m2 in a 24-hour infusion every 3 weeks. The optimal sequence of chemotherapeutic agents was investigated by reversing the order of administration in the second cycle and by collecting a total of six pharmacokinetic blood samples per cycle from all patients during the first and second cycles. The sequence of administration did not influence the pharmacokinetics of docetaxel. Prostate-specific antigen (PSA) responses were observed in four out of nine patients, with a PSA response rate of 44.4% (complete response + partial response). The treatment was well tolerated. No grade IV toxicities were recorded and grade III leucopenia resulted in dose-reductions in 6 cycles (13.3%). The pharmacokinetic parameters of docetaxel were similar in both sequences. Our recommendation for further phase II studies is ifosfamide followed by low-dose docetaxel. Further phase II efficacy studies are warranted.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Prostatic Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/blood , Area Under Curve , Docetaxel , Humans , Ifosfamide/administration & dosage , Ifosfamide/blood , Ifosfamide/pharmacokinetics , Male , Metabolic Clearance Rate/drug effects , Metabolic Clearance Rate/physiology , Prostatic Neoplasms/blood , Taxoids/administration & dosage , Taxoids/blood , Taxoids/pharmacokinetics
16.
Pancreatology ; 3(1): 55-63, 2003.
Article in English | MEDLINE | ID: mdl-12649565

ABSTRACT

BACKGROUND: The therapeutic efficacy of intratumoral instillation of genetically engineered, CYP2B1-expressing, microencapsulated cells in combination with ifosfamide had been previously demonstrated in xenografted human pancreatic ductal carcinomas [Gene Ther 1998;5:1070-1078]. Prior to a clinical study, the feasibility of an intra-arterial application of microencapsulated cells to the pancreas and its consequences to the organ had to be evaluated. MATERIAL AND METHODS: Microencapsulated, CYP2B1-producing cells were instilled both in vivo (transfemoral angiographical access) and in vitro (perfusion model) in the splenic lobe of the pig pancreas. In vivo, animals were monitored clinically for 7 days, then treated with ifosfamide and sacrificed. In vitro, ifosfamide was administered intra-arterially. RESULTS: In all animals, 100 microcapsules could be instilled safely via the femoral route without clinical, biochemical or histological signs of pancreatitis. Histological examination revealed partial obstruction of small arteries by the capsules, without causing any parenchymal damage. In vitro, instillation reduced blood flow by half. Ifosfamide, also in combination with the capsules, did not add any damage to the pancreas. CONCLUSION: Intra-arterial instillation of microencapsulated cells to the pig pancreas is feasible and safe. Neither pancreatitis, foreign body reactions nor circulatory disturbances were observed. Clinical application of this genetically enhanced chemotherapeutic method seems possible.


Subject(s)
Antineoplastic Agents, Alkylating/administration & dosage , Cell Transplantation/methods , Ifosfamide/administration & dosage , Pancreas/blood supply , Pancreas/drug effects , Angiography , Animals , Antineoplastic Agents, Alkylating/blood , Antineoplastic Agents, Alkylating/metabolism , Antineoplastic Agents, Alkylating/pharmacokinetics , Capsules , Cell Line , Cytochrome P-450 CYP2B1/biosynthesis , Cytochrome P-450 CYP2B1/genetics , Feasibility Studies , Femoral Artery , Genetic Engineering , Humans , Ifosfamide/blood , Ifosfamide/metabolism , Ifosfamide/pharmacokinetics , In Vitro Techniques , Instillation, Drug , Microspheres , Pancreas/pathology , Regional Blood Flow/drug effects , Splenic Artery/diagnostic imaging , Swine
17.
Int J Clin Pharmacol Ther ; 40(8): 376-81, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12467306

ABSTRACT

OBJECTIVE: This study focuses on the pharmacokinetics of trofosfamide (TRO) and metabolites after oral administration of TRO. METHODS: Twelve patients with solid tumors and non-Hodgkin lymphomas were treated with 450 mg TRO orally for 7 days. TRO and the stable metabolites ifosfamide (IFO), cyclophosphamide (CYC), 2- and 3-dechloroethylifosfamide (2-DCE, 3-DCE) were determined by GC and the sum of the 4-OH-metabolites was measured by HPLC. RESULTS: A fast metabolism of TRO with a half-life of about 1 h was observed. IFO was the main stable metabolite, whereas CYC was only detected in minor quantities. The peak levels and the AUC of the 4-OH-metabolites were 9.5 and 4.3 times higher than observed after an equimolar IFO dose. Only 6% of the administered dose was recovered in urine within 24 hours as stable metabolites. TRO was under limit of detection. CONCLUSIONS: Our results confirm that dechloroethylation of TRO to IFO is a major metabolic pathway. Additionally, we found considerable 4-hydroxylation not shown previously. With respect to the low levels of IFO and CYC observed, the sum of 4-OH-metabolites cannot be explained by hydroxylation of these metabolites only. Hence, we assume a direct 4-hydroxylation of TRO occurring to a high extent. Bioavailability of TRO could not be calculated directly, because TRO is only available as an oral formulation. The bioavailability of oral IFO, however, is reported to be almost 100%. Therefore, after normalization of the dose, a bioavailability of 32% for IFO after oral TRO could be calculated. Thus, in contrast to previous reports, direct 4-hydroxylation of TRO seems to be the main metabolic pathway.


Subject(s)
Antineoplastic Agents, Alkylating/pharmacokinetics , Cyclophosphamide/analogs & derivatives , Cyclophosphamide/pharmacokinetics , Adult , Aged , Antineoplastic Agents, Alkylating/blood , Antineoplastic Agents, Alkylating/metabolism , Antineoplastic Agents, Alkylating/therapeutic use , Area Under Curve , Biological Availability , Cyclophosphamide/blood , Cyclophosphamide/metabolism , Cyclophosphamide/therapeutic use , Dose-Response Relationship, Drug , Female , Humans , Ifosfamide/blood , Ifosfamide/metabolism , Ifosfamide/pharmacokinetics , Lymphoma, Non-Hodgkin/drug therapy , Male , Middle Aged , Molecular Structure
18.
Biopharm Drug Dispos ; 22(3): 99-108, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11745912

ABSTRACT

The distribution of ifosfamide (IF) and its metabolites 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE), 4-hydroxyifosfamide (4OHIF) and ifosforamide mustard (IFM) between plasma and erythrocytes was examined in vitro and in vivo. In vitro distribution was investigated by incubating blood with various concentrations of IF and its metabolites. In vivo distribution of IF, 2DCE, 3DCE and 4OHIF was determined in 7 patients receiving 9 g/m(2)/72 h intravenous continuous IF infusion. In vitro distribution equilibrium between erythrocytes and plasma was obtained quickly after drug addition. Mean (+/-sem) in vitro and in vivo erythrocyte (e)-plasma (p) partition coefficients (P(e/p)) were 0.75+/-0.01 and 0.81+/-0.03, 0.62+/-0.09 and 0.73+/-0.05, 0.76+/-0.10 and 0.93+/-0.05 and 1.38+/-0.04 and 0.98+/-0.09 for IF, 2DCE, 3DCE and 4OHIF, respectively. These ratios were independent of concentration and unaltered with time. The ratios of the area under the erythrocyte and plasma concentration--time curves (AUC(e/p)) were 0.96+/-0.03, 0.87+/-0.07, 0.98+/-0.06 and 1.34+/-0.39, respectively. A time- and concentration-dependent distribution--equilibrium phenomenon was observed with the relative hydrophilic IFM. It is concluded that IF and metabolites rapidly reach distribution equilibrium between erythrocytes and plasma; the process is slower for IFM. Drug distribution to the erythrocyte fraction ranged from about 38% for 2DCE to 58% for 4OHIF, and was stable over a wide range of clinically relevant concentrations. A strong parallelism in the erythrocyte and plasma concentration profiles was observed for all compounds. Thus, pharmacokinetic assessment using only plasma sampling yields direct and accurate insights into the whole blood kinetics of IF and metabolites and may be used for pharmacokinetic-pharmacodynamic studies.


Subject(s)
Antineoplastic Agents, Alkylating/blood , Erythrocytes/metabolism , Ifosfamide/blood , Plasma/metabolism , Antineoplastic Agents, Alkylating/chemistry , Antineoplastic Agents, Alkylating/pharmacokinetics , Area Under Curve , Humans , Ifosfamide/chemistry , Ifosfamide/pharmacokinetics
19.
Eur J Clin Pharmacol ; 57(6-7): 467-77, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11699611

ABSTRACT

OBJECTIVE: The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in patients with soft tissue sarcoma. METHODS: Twenty patients received 9 or 12 g/m2 ifosfamide administered as a 72-h continuous intravenous infusion. The population pharmacokinetic model was built in a sequential manner, starting with a covariate-free model and progressing to a covariate model with the aid of generalised additive modelling. RESULTS: The addition of the covariates weight, body surface area, albumin, serum creatinine, serum urea, alkaline phosphatase and lactate dehydrogenase improved the prediction errors of the model. Typical pretreatment (mean +/- SEM) initial clearance of ifosfamide was 3.03 +/- 0.18 l/h with a volume of distribution of 44.0 +/- 1.8 l. Autoinduction, dependent on ifosfamide levels, was characterised by an induction half-life of 11.5 +/- 1.0 h with 50% maximum induction at 33.0 +/- 3.6 microM ifosfamide. Significant pharmacokinetic-pharmacodynamic relationships (P = 0.019) were observed between the exposure to 2- and 3-dechloroethylifosfamide and orientational disorder, a neurotoxic side-effect. No pharmacokinetic-pharmacodynamic relationships between exposure to 4-hydroxyifosfamide and haematological toxicities could be observed in this population.


Subject(s)
Antineoplastic Agents, Alkylating/pharmacokinetics , Cyclophosphamide/analogs & derivatives , Ifosfamide/analogs & derivatives , Ifosfamide/pharmacokinetics , Sarcoma/metabolism , Adult , Aged , Algorithms , Antineoplastic Agents, Alkylating/therapeutic use , Antineoplastic Agents, Alkylating/urine , Cyclophosphamide/blood , Cyclophosphamide/urine , Female , Humans , Ifosfamide/blood , Ifosfamide/therapeutic use , Ifosfamide/urine , Infusions, Intravenous , Male , Metabolic Clearance Rate , Middle Aged , Models, Biological , Sarcoma/drug therapy
20.
Clin Pharmacol Ther ; 70(2): 132-41, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11503007

ABSTRACT

BACKGROUND: The autoinducible metabolic transformation of the anticancer agent ifosfamide involves activation through 4-hydroxyifosfamide to the ultimate cytotoxic ifosforamide mustard and deactivation to 2- and 3-dechloroethylifosfamide with concomitant release of the neurotoxic chloroacetaldehyde. Activation is mediated by cytochrome P450 (CYP) 3A4 and deactivation by CYP3A4 and CYP2B6. The aim of this study was to investigate modulation of the CYP-mediated metabolism of ifosfamide with ketoconazole, a potent inhibitor of CYP3A4, and rifampin (INN, rifampicin), an inducer of CYP3A4/CYP2B6. METHODS: In a double-randomized, 2-way crossover study a total of 16 patients received ifosfamide 3 g/m(2) per 24 hours intravenously, either alone or in combination with 200 mg ketoconazole twice daily (1 day before treatment and 3 days of concomitant administration) or 300 mg rifampin twice daily (3 days before treatment and 3 days of concomitant administration). Plasma pharmacokinetics and urinary excretion of ifosfamide, 2- and 3-dechloroethylifosfamide, and 4-hydroxyifosfamide were assessed in both courses. Data analysis was performed with a population pharmacokinetic model with a description of autoinduction of ifosfamide. RESULTS: Rifampin increased the clearance of ifosfamide at the start of therapy at 102%. The fraction of ifosfamide metabolized to the dechloroethylated metabolites was increased, whereas exposure to the metabolites was decreased as a result of increased elimination. The fraction metabolized and the exposure to 4-hydroxyifosfamide were not significantly influenced. Ketoconazole did not affect the fraction metabolized or the exposure to the dechloroethylated metabolites, whereas both parameters were reduced with 4-hydroxyifosfamide. CONCLUSIONS: Coadministration of ifosfamide with ketoconazole or rifampin did not produce changes in the pharmacokinetics of the parent or metabolites that may result in an increased benefit of ifosfamide therapy.


Subject(s)
Antineoplastic Agents, Alkylating/pharmacokinetics , Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 Enzyme System/drug effects , Cytochrome P-450 Enzyme System/metabolism , Enzyme Inhibitors/pharmacology , Ifosfamide/pharmacokinetics , Ketoconazole/pharmacology , Rifampin/pharmacology , Adult , Aged , Antibiotics, Antitubercular/pharmacology , Antifungal Agents/pharmacology , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/blood , Area Under Curve , Bayes Theorem , Cross-Over Studies , Cytochrome P-450 CYP2B6 , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme System/biosynthesis , Drug Administration Schedule , Enzyme Induction/drug effects , Enzyme Inhibitors/administration & dosage , Female , Humans , Ifosfamide/administration & dosage , Ifosfamide/blood , Ketoconazole/administration & dosage , Male , Middle Aged , Mixed Function Oxygenases/drug effects , Mixed Function Oxygenases/metabolism , Oxidoreductases, N-Demethylating/drug effects , Oxidoreductases, N-Demethylating/metabolism , Rifampin/administration & dosage , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...